MedTrace Logo

Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: A Prospective Study

NCT07115576 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2025-12-16

No results posted yet for this study

Summary

Title:

Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: A Prospective Study

Purpose:

The goal of this clinical trial is to learn if single-session radiofrequency ablation (RFA) can effectively reduce the volume of benign thyroid nodules in adults. It will also evaluate the safety of the RFA procedure.

The main questions it aims to answer are:

1. Does RFA procedure reduce the size of thyroid nodules (measured by volume reduction rate - VRR)?
2. What medical problems or complications do participants experience after undergoing RFA?
3. How does RFA affect thyroid hormone levels (TSH, FT4)?
4. Is RFA equally effective in purely cystic nodules, solid nodules, and predominantly cystic nodules?

Comparator:

This is a single-arm study, so there is no placebo or comparison treatment group. All participants will undergo RFA, and the results will be assessed over time.

Participants will:

* Undergo one session of RFA for benign thyroid nodules.
* Be followed up with clinical visits and ultrasound assessments at 1, 6, and 12 months.
* Have thyroid hormone levels tested and nodule size measured by ultrasound at each follow-up.
* Be monitored for any side effects or complications such as voice changes, pain, or bleeding.

Conditions

  • Benign Thyroid Nodules

Interventions

PROCEDURE

Radiofrequency ablation alone

Radiofrequency ablation (RFA) is a minimally invasive procedure used to treat benign thyroid nodules without surgery. It involves inserting a thin, needle-like electrode into the nodule under ultrasound guidance. Using high-frequency alternating current, the electrode generates heat to destroy targeted thyroid tissue, causing the nodule to shrink over time.

Sponsors & Collaborators

  • Da Nang Family General Hospital

    collaborator OTHER

  • Hue University of Medicine and Pharmacy

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-10
Primary Completion
2026-02-10
Completion
2026-04-10

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07115576 on ClinicalTrials.gov